Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029679 · ClinicalTrials.gov registry record · Phase 1
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
A Phase 1 study of Asthma, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT00029679 is a Phase 1 study of Asthma that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 280 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00029679, a Phase 1 study of Asthma, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess clinical efficacy and/or adverse effects of dietary borage oil (which contains gamma-linolenic acid \[GLA\]) and Ginkgo biloba in patients with mild persistent to moderate asthma.
Conditions Studied
Interventions
- DRUG Gingko biloba
- DRUG Borage oil
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2000-09 |
| Est. Completion | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029679
The ClinicalTrials.gov registry entry for NCT00029679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Gingko biloba is the first listed.
NCT00029679 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00029679 about?
NCT00029679 is a clinical study titled "Borage Oil and Ginkgo Biloba (EGb 761) in Asthma". This study will assess clinical efficacy and/or adverse effects of dietary borage oil (which contains gamma-linolenic acid \[GLA\]) and Ginkgo biloba in patients with mild persistent to moderate asthma.
What is the current status of trial NCT00029679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2000-09. Estimated completion is 2005-07.
What conditions does trial NCT00029679 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00029679?
The interventions under investigation include: Gingko biloba (DRUG), Borage oil (DRUG).
Who is sponsoring clinical trial NCT00029679?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00029679 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.